The authors precisely note The shortage of randomized managed trials for orthopaedic indications—which means we are able to’t confidently say it really works, what the true facet-impact profile is, or what a “safe dose” would be in the real earth (systematic review, 2024).When the purpose is “much less downtime, far more education,” the